KURA Kura Oncology, Inc.
USHealthcareAs of 2026-07-08 16:00
Why KURA matters now
Kura Oncology, Inc. (KURA) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.12 with +1.08% on the session and $1.08B in market capitalization; recent performance reads 1-month +10.83% and YTD -4.43%.
The latest financial table shown here is Q1 2026, with revenue of $18.3M, net income of $-73.3M, and EPS of $-0.83. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.6%.
The latest indexable market news headline is "Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $24.00; recent insider activity includes Malley Thomas filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.16
P/S
12.31
EV/EBITDA
-2.97
DCF Value
$18.99
FCF Yield
-9.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.7%
Operating Margin
-443.5%
Net Margin
-411.2%
ROE
-142.0%
ROA
-45.1%
ROIC
-57.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $18.3M | $-73.3M | $-0.83 |
| Q4 2025 | $17.3M | $-81.0M | $-0.92 |
| FY 2025 | $67.5M | $-278.7M | $-3.18 |
| Q3 2025 | $20.8M | $-74.1M | $-0.85 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$22.25
Target (Median)
$24.00
Target Range
$15.00 - $24.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.36
Kura Oncology, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to discovering and advancing cancer treatments within the United States. Its therapeutic portfolio primarily features small-molecule compounds engineered to combat various cancers. Among its leading drug candidates is ziftomenib, a small-molecule agent designed to disrupt the interaction of menin-Lysine K-specific Methyltransferase 2A proteins. This inhibitor is being developed for specific genetic forms of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Another prominent candidate is tipifarnib, an orally administered farnesyl transferase inhibitor currently undergoing Phase II clinical assessment for both solid tumors and blood-related conditions. The company has also established a clinical collaboration with Novartis to evaluate the combined therapeutic potential of tipifarnib and alpelisib. This joint effort targets patients with head and neck squamous cell carcinoma whose tumors exhibit HRAS overexpression or specific PIK3CA mutations or amplifications. Founded in 2014, Kura Oncology, Inc. operates from its headquarters in San Diego, California.